Randox Horse Tales | Rose Paterson on Foinavon’s 100-1 dream come true in the 1967 Grand National
The countdown to the Randox Health Grand National continues, with only two weeks to go before the first day of the Festival.
And there’s no one who knows the history of the race better than Aintree Racecourse Chairman, Rose Paterson. Today she shares her memories of her favourite horse, Foinavon, and why his unexpected Grand National win in 1967 has become an iconic moment in the history of the great race.
Foinavon is the Forrest Gump of Grand National history, the horse who became immortal despite his best endeavours.
Bred in the purple by the great stallion Vulgan, he was bought as a youngster by Anne, Duchess of Westminster, one of the pre-eminent National Hunt owners of her generation and sent to Tom Dreaper, the Willie Mullins of his day, along with another young horse, Arkle. Both horses were named after mountains on the Westminsters’ Invernesshire estate.
However, while Arkle went on to win three Cheltenham Gold Cups and become the benchmark for NH greatness, Foinavon’s trajectory was in a different direction. Pat Taaffe, Dreaper’s stable jockey, said of him “I never came across a horse with less ambition.”
The final straw was when after a heavy fall, Taaffe scrambled to his feet, desperately worried for Foinavon, who had failed to rise. He found him sitting comfortably on the ground, eating grass.
It was a short journey from this incident to Doncaster sales, where he was snapped up by small time trainer and part-time farrier John Kempton, entirely because he had qualified for the Grand National and one of his few owners, Cyril Watkins, was desperate for a runner. By this time, Foinavon had acquired a white goat named Suzie as a companion, who travelled everywhere with him and with whom he developed a love/hate relationship.
A year later, after 17 consecutive losing runs, Foinavon was ready to have a go. He had already run in the Gold Cup three weeks earlier, at 500-1 and no less than twice since then, without distinction. His jockey, John Buckingham, was the trainer’s third choice and neither owner or trainer could be bothered to make the five hour journey to Aintree.
When the disaster caused by loose horses Popham Down and April Rose unfolded at the smallest fence on the course, universally described as “the one after Becher’s,” Foinavon was so far behind the leaders that he was able to pop a gap in the fence and trundle on to the Canal Turn, leaving a scene of mayhem in his wake.
It was the combination of an intelligent, experienced jockey and an unusually placid horse that probably won him the race.
At the time, the result was seen as a disaster and an embarrassing fiasco. 50 years on, Foinavon’s win seems an iconic moment in the history of the great race.
It was about luck, fate, the victory of the outsider, the 100 – 1 dream come true.
Not for nothing was the first winner of the Grand National called Lottery and there is an equally good reason why the 7th and 23rd fence is now known as Foinavon.
For more information about Randox Horse Tales please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
2017 Randox Health Grand National Trophy Statue unveiled at Aintree Racecourse
A giant replica of the 2017 Randox Health Grand National trophy is being installed at Aintree Racecourse ahead of the world’s greatest horse race. The design was unveiled for the first time today during the Northern media lunch.
The statue standing at almost 6 meters, which will be seen by over 600 million people during the three day festival, depicts the same level of detail as the real trophy. The stunning piece is solid silver gilded with gold, and depicts horses galloping through strands of DNA.
A spot will be marked out near the statute directing race-goers where to stand to get a picture of them ‘holding’ the trophy. It is part of Randox Health’s plan to get the nation to #FeelLikeAWinner during the festival, even if they won’t be at Aintree. They hope people at the racecourse will share the trophy images on social media with people at home posting selfies with their cherished trophies!
Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, commented;
“With the Randox Health Grand National being the greatest horse race in the world we wanted to give everyone a chance to feel like a winner throughout the festival. We’re very proud of the trophy and its one people can enjoy too. We want to give everybody the opportunity to feel part of this year’s festival even if they’re not here, which is why we’re encouraging them to share their own trophy selfies with the racing fans at Aintree. The Randox Health Grand National is a national occasion we want to share and we hope that we can encourage that.”
John Baker, Managing Director for Aintree Racecourse, commented;
“We’re delighted and honoured to work with Randox as a long term partner and we look forward to many years of success. With less than three weeks to go until the Randox Health Grand National Festival, we’re in great shape with the Aintree site looking tremendous and ticket sales going very well. We’re anticipating three days of thrilling racing with high quality entries and we look forward to plenty of fun and excitement off the track as well. The Aintree and Randox teams are working extremely hard to put on the best possible experience for our racegoers so we look forward to opening the gates on Thursday 6 April and welcoming everyone for a fantastic three days.”
The official reveal of the trophy statue has come after the announcement that for each of its five years of sponsorship, Randox Health, the title partner of the Randox Health Grand National, will create a unique winner’s trophy, and each member of the winning team – trainer, jockey and groom – will receive their own trophy in recognition of the teamwork that goes into achieving such monumental success.
The coveted trophy was unveiled by Sir Anthony McCoy and Dr Peter FitzGerald at the Weights Evening Reception at the Victoria and Albert Museum in London.
For more information about Randox Health Grand National Horse please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox celebrates British Science Week 2017
Randox celebrates British Science Week 2017
Last week was British Science Week 2017, an annual campaign that aims to inspire innovation and celebrate science. To mark the occasion, Randox Laboratories got involved by celebrating the innovation of each Randox product group. The product groups within Randox shared a series of posts, videos and blogs showcasing the #ScienceBehindRandox throughout British Science Week.
Randox
To initiate the Randox British Science Week campaign, Randox shared this video, which highlights the company’s dedication to improving health worldwide. The video provides an introduction about each product group, however throughout British Science Week, each product group has gone into further detail about the #ScienceBehindRandox.
Randox Careers, the RX series, Randox Reagents, Randox Quality Control, Randox Toxicology, Randox Biosciences, Randox Testing Services, & Randox Food Diagnostics all got involved in the British Science Week Campaign. You can read a snippet of each product groups post below, with videos and links to the full content also provided. We hope you enjoy learning about the #ScienceBehindRandox.
Randox – Dedicated to improving health wordwide.
Randox Careers
Joanne Darragh spent some time with Randox Careers to discuss her role as R&D Toxicology Manager.
“Working in this area has been both challenging and exciting as we are at the cutting edge of assay development. We work in a great team and we work along very closely alongside other departments such as Marketing & Sales so that we are in close contact with what the customer needs, which means we are producing relevant tests very quickly and effectively. Every day brings a new challenge.”
– Joanne Darragh, R&D Toxicology Manager
Listen to what Joanne had to say on the video above
Randox RX series
As part of British Science Week, the RX series caught up with Daniel Melly, one of our very talented Mechanical Design Engineers based in Randox Teoranta in Dungloe, Ireland.
Daniel was an integral part of the team involved in the design of our new semi-automated analyser, the RX misano. The RX series asked Daniel a few questions about why Randox created this analyser, the design process involved in creating such a unique system, and what his favourite features are.
“Randox set out in creating the RX misano with the philosophy of supplying the customer with a more modern, reliable, and aesthetically pleasing analyser than those that are currently available on the market. Robust part selection was always at the fore of any design decisions, and we feel that we have delivered on all of these requirements.”
– Daniel Melly, Randox Mechanical Design Engineer
Read the full interview the RX series had with Daniel here
The RX misano is currently unavailable to purchase in Germany
Randox Reagents
One unique test by Randox, adiponectin, is becoming an increasingly significant biomarker for health professionals. Low levels have been linked with several illnesses including metabolic syndrome, cancer and cardiovascular disease.
What is adiponectin?
Adiponectin is a protein hormone produced and secreted by fat cells called adipose tissue. Adiponectin is normally found in relatively high concentrations in healthy individuals. Its role in the body is to regulate the metabolism of lipids and glucose, which influences the body’s response to insulin and inflammation.
At Randox, our R&D Scientists are helping to change healthcare. By investing heavily into research and development to develop unique diagnostics tests, such as the adiponectin test, Randox provide doctors with the ability to identify disease risk sooner- offering the opportunity to prevent illness, rather than the need to find a cure.
Read the full Randox Reagents blog entry here
Randox Quality Control
One Simple Change to Randox Quality Control can save your laboratory time and money.
Randox Quality Control are a world leading manufacturer of true third party controls with over 390 analytes covering Antioxidants, Blood Gas, Cardiac Markers, Routine Chemistry, Coagulation, Haematology, Diabetes, Immunoassay, Immunology, Lipids, POCT, Therapeutic Drugs, Toxicology and Urine Chemistry, providing complete test menu consolidation. Randox Quality Control produces the most consistent material available with the most accurate target values.
Randox Quality Control guarantee to simplify QC practice in any laboratory, just ask one of their 60,000 users worldwide.
Find out more information about Randox Quality Control in the video above
Randox Toxicology
Randox Toxicology provides trusted solutions for the screening for drugs of abuse. With significant reinvestment in Research and Development, we persistently stay ahead of this ever challenging market. Being the first to develop New Psychoactive Substances tests such as fentanyl, bath salts and flakka allows us to maintain our position as a global leader.
Our pioneering technology has created a number of advancements in the field of toxicology. In particular, our patented Biochip Array Technology which can simultaneously screen from a multi-analyte testing platform, achieving a complete immunoassay profile from the initial screening phase.
Read the full Randox Toxicology blog post here
Randox Biosciences
During British Science Week, we are delighted to introduce you to our latest development utilising this technology; our Gastropanel Array,* a multiplex test engineered to diagnose those at risk of developing peptic ulcers and gastric cancer using non-invasive methods.
Our Gastropanel Array encompasses two quantitative assays, a H. pylori assay for the detection of antibodies produced in response to a H. pylori infection, a common cause of gastric cancer1 as well as a 3plex Gastropanel assay, for the detection of pepsinogen I (PGI), pepsinogen II (PGII) and gastrin 17 (G17).
Currently recorded as the world’s 5th most common cancer, the majority of gastric cancer cases are diagnosed after presenting as an emergency, when treatment may be less effective due to the cancer being at an advanced stage, highlighting the need for the availability of diagnostics tests like our Gastropanel Array to enable practitioners to administer prompt treatment and ultimately increase survival rates on a global scale.
Read the full Randox Biosciences blog here
Randox Testing Services
Randox Testing Services have shown how they are at the forefront of continually reacting and developing tests for NPS. NPS (formerley known as Legal Highs) have had devastating effects on users since emerging in the UK in 2008. These substances are highly dangerous and have caused unnecessary deaths. This is due to the effects from different elements used in production. Legislation concerning the substances changed in 2016 with the implementation of the Psychoactive Substance Act.
How have Randox Testing Services implemented change? Find out in the video above
Randox Food Diagnostics
Of the 41 antibiotics that are approved for use in food-producing animals by the FDA, 31 are medically important for human health. Randox Food Diagnostics provides advanced screening solutions for 94% of these antibiotics including beta-lactams, quinolones and tetracyclines, allowing you to ensure the integrity of your end product without compromising quality. Randox Food provides multiplex screening solutions validated across a range of matrices including urine, serum, tissue, milk, honey and feed.
The Evidence Investigator matched with Biochip Array Technology (BAT) provide the end user with fast, reliable results to aid in ensuring your produce is antibiotic free. BAT provides a platform for the simultaneous determination of multiple drug residues from a single sample using miniaturised immunoassays with implications in the reduction of sample/reagent consumption and an increase in the output of test results.
To read Randox Food Diagnostics full blog click here
We hope you enjoyed our informative British Science Week content from each of our Product Groups.
Look out for our Quiz later this week to test your knowledge on the #ScienceBehindRandox
Randox Horse Tales | Katie Walsh on the partnership with Seabass that made her the most successful female jockey of all time
With less than three weeks’ to go before the Randox Health Grand National, we’re really starting to feel the excitement!
Those who’ve ridden over the famous fences at Aintree never forget it. The most successful female jockey of all time, Katie Walsh, shares her memories of Seabass in the 2012 Grand National, when she came third.
I remember every single bit of it. You don’t forget things like that.
It was a fantastic time and I had some brilliant months in the lead up to it. I won a couple of good races in the build up to the Grand National.
And for Seabass to be the horse that I rode that day, made it all the more magical. This is definitely at the top of my list.
He’d been trained by my father and we’ve been involved with horses for so long that we know how hard it is to have a horse for the Grand National – things can change every day. It’s like someone saying, “I’m going to be President.” That’s how slim the chances are for it to all work out, so I really appreciate how lucky we were to be there.
Seabass is a gorgeous horse and I absolutely love him.
The biggest difficulty we had was keeping him sound. Seabass was a lovely horse but he wasn’t the easiest to keep sound. You see that a lot in elite athletes – sometimes it’s just incredibly difficult to stay fit. And to be in with a shot of getting into the National, you have to keep a horse high enough in the handicaps so it’s constant work – you’ve got to be really careful what you do and how you treat them.
If you look back at his record, Seabass was off for a couple of seasons simply because he has legs of glass, he’s really fragile. There were many different problems over the years which had to be treated and we did a lot of swimming with him. A lot a lot of work went into minding his legs!
The actual race – I could tell you every moment. It was like a dream, the whole ride was fantastic and everything worked out super! Seabass travelled so well – it was a competitive year that year and on another he might have won.
But I was over the moon when we crossed the line in third.
It meant a lot to people that a female jockey had done so well. It featured heavily in the interviews I did afterwards and still does to be honest.
The whole family were there– Ruby wasn’t actually riding himself that day, he’d had a fall earlier. So they were all watching. We’re a pretty special unit – very close – and they were thrilled for us.
Once it was over though, I went straight into the usual routine. In fact I jumped in the car and went to Newmarket. Life goes on!
But once you’ve achieved something like that in the Grand National life does change. Off the back of it I became an Aintree ambassador which is a huge honour and something that I absolutely love.
I can’t wait for the Randox Health Grand National this year!
For more information about Randox Horse Tales please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox Biosciences and Dana-Farber Cancer Institute Celebrate Success of Transatlantic Partnership
Today, Randox Biosciences and Dana Farber Cancer Institute highlighted the milestones achieved during their joint partnership. The collaborative partnership was the focus of the Boston-Ireland Precision Medicine Seminar with partners the City of Boston and the Massachusetts Life Science Center (MLSC).
The City of Boston Office of Economic Development and the Massachusetts Life Science Center are collaborating with Randox Biosciences on an innovative event to discuss the Boston-Ireland linkage in the field of Precision Medicine. The event will build business and science relationships between leading life science organizations. The program will highlight Boston as a global life science hub and illustrate why global leaders like Randox are seeking to build business partnerships in the area.
“Dana-Farber is a world-renowned name in the field of oncology and it is great to be working on this exciting new technology which is being developed in the lab of Dr. Novina.” Marshall Dunlop of Randox Laboratories said.
In the last year, the clinical diagnostics and life sciences provider Randox Laboratories has established a collaborative agreement with Dr. Carl Novina at the Dana-Farber Cancer Institute and Harvard Medical School. The goal of this collaboration is to develop therapeutic antibodies that will be incorporated into a platform technology that can reprogram patients’ immune systems to attack cancers.
“I am excited to work with Randox and use these important antibody technologies to help develop a novel cancer therapy that could potentially make a real difference for cancer patients.” said Dr. Carl Novina, Dana Farber Cancer Institute.
The Randox BioSciences and Dana Farber relationship highlights the close ties between Boston, Massachusetts and Ireland and provides another example of the strengths of Boston and Ireland in the life sciences sector. The life sciences industry continues to thrive all across Boston, from Longwood Medical Area – a world-famous medical campus with over 43,000 scientists, researchers, and staff including over 19,000 students – to the South Boston Waterfront District, the city’s newest cluster of high tech research, development, and manufacturing firms.
The City of Boston Chief of Economic Development John Barros said, “Mayor Martin J. Walsh is proud of Boston’s historic links with Ireland and the diverse economic bridges these links have created today. Within the life sciences alone, our researchers and businesses work together in new ways every day to shape how we treat, cure, and innovate together. By partnering with Randox and other leaders in the field, we continue to tackle global challenges together. Here at the City of Boston, we are committed to maintaining open doors as a global and welcoming city. These international partnerships will continue to play an active role in fostering opportunities for collaboration and growth.”
“Collaboration is the key ingredient that makes Massachusetts the best place in the world to innovate,” said Travis McCready, President & CEO of the MLSC. “It is great to see Randox collaborating with the leading scientists at the Dana-Farber Cancer Institute, toward the development of improved, targeted treatments for cancer patients.”
For more information about the Precision Medicine Seminar in Boston please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Randox Horse Tales | Oliver Sherwood shares his memories of Many Clouds, The People’s Horse
There was only one horse that Oliver Sherwood wanted to write about when he was asked to take part in Horse Tales – his 2015 Grand National winner Many Clouds. He was the horse of a lifetime for the Lambourn-based trainer who was hooked the moment he saw him. Clouds tragically died earlier this year and Sherwood says he misses him every day.
The minute I saw him, I knew there was something special. Of course, we all think that. But there was something about Clouds that I just liked from the start.
I had come to look over Mr Hemmings’ young horses when I first saw Clouds. He was a raw, barely broken three year old, and I saw an individualism about him, a character that appealed. From that moment I wanted to be the one to train him.
I’m sure other trainers saw Clouds’ potential too but every time I went to Mr Hemmings’ place, I’d mention to Mick Meagher, the manager, how much I liked him. However I really didn’t expect to get him, so when Mr Hemmings started allocating his horses and Mick called to say they were sending him to me, I was surprised and delighted.
When we started the serious training, I thought he was above average. You can’t be certain – I’ve seen before how horses show form but then can’t perform on the racecourse. That didn’t happen with Clouds. He won on his debut at Wetherby in February 2012, crossing the line 10-15 lengths in front. Right then I knew my gut had been right – he was going to be special. I started hoping and planning for the Hennessey Gold Cup.
He had a summer holiday after that and thickened out. When he came back, he won a handful of hurdles, and came second in the EDF Final the Saturday before Cheltenham, carrying top weight. We were certain that hurdles would be a stepping stone for him.
He was a natural chaser. In 2014 – 15 he won at Carlisle and then won the Hennessey. The rest is history. He won at Cheltenham in January though disappointed in the Gold Cup. But then he won at Aintree in 2015 and that put him on a different level.
As with so many fairy tales from the National, it was unexpected. I’d thought it was too soon for him, but I was persuaded to give it a go. It was a sensational victory. It was the second fastest time – 8 minutes 56.8 seconds, and he did it with 11 stone 9 pounds – almost the top weight. In fact no other horse had carried a higher weight and won at Aintree since Red Rum in ’74. His jockey – Leighton Aspell – said it was the best ride he’d ever had over the fences.
I was staggered by how worldwide the National is. For many trainers you want to win the Gold Cup, it’s the 100m sprint, but when I was being interviewed for the first time by broadcasters in Australia, the US and Japan after winning in 2015, they saw it as the pinnacle.
One thing is absolutely true though – you’ll never forget it. You try to explain to people who have never had horses – but you simply can’t express the thrill of seeing your horse in your colours pass the finishing post in the lead. It was Sir Fred Pontin trying to get that across to Mr Hemmings that got him into racing in the first place. He’d won with Specify in 1971, and showed Mr Hemmings the trophy. He ended up bequeathing it to him in his will – by which stage Mr Hemmings had already won one himself with Hedgehunter.
God puts you on this planet and you are what you are. Clouds, he was a performer, a competitor. He loved to race. He was a nervous horse, a bit spooky but he got more confident as he grew older. He was the proverbial gentle giant, he always wanted to please. He loved his work, he was always very keen to get out and race. Leighton was the only one who schooled and raced him.
Clouds’ last race was his best ever performance. He won by a head in a photo-finish in the Cotswold Chase at Cheltenham but suddenly suffered a severe pulmonary haemorrhage and despite the best efforts of the team on the course, he died just afterwards.
We’ve been overwhelmed by the reaction from people. There have been over a thousand letters – never mind emails and Facebook messages – from all over the world. My wife has responded to every single one of them. People responded to him- they saw he was a trier and they loved that. People could relate to him – in a way he became the people’s horse.
When he won at Aintree thousands of people came out to see him when he came home. Everyone celebrated his win, and that depth of feeling continues today. Our local open day has been renamed after him, and in the village a bench will be placed in his memory thanks to the local council and the Jockey Club. At a party on Saturday here, we still had kids coming up and asking about Clouds. It’s just staggering the impact he had and the inspiration he gave to so many. I am certain he’s bringing a lot of new people into racing.
He was cremated and his ashes were returned to the Isle of Man where Mr Hemmings lives. His shoes will be mounted on a wooden plaque, and his best races inscribed on it. We’ve still got the plaque which was mounted on his box after the won the Grand National.
I’ll never forget Clouds. He will always be in my memories and those of the whole team here in Rhonehurst. Yet I’m glad he went out on a high. I’d rather that than have him suffer an injury. Death happens to us all – I would love to go as he did.
For more information about Randox Horse Tales please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
How Randox R&D Scientists are helping to change healthcare: An introduction to diagnostics for BSW 2017
In celebration of British Science Week 2017, we will be giving you an introduction to diagnostics, and exploring how Randox Scientists are helping to change healthcare.
You may or may not already know that Randox are one of the leading diagnostics companies globally. But what exactly does clinical diagnostics involve? It is one of the fundamental steps of finding out what is wrong with a person when they are ill. Read on to find out a bit more about diagnostics, and how the Randox Reagents R&D Scientists are helping to change healthcare globally!
What is a diagnostic test?
A diagnostic test is any kind of analysis performed on a patient sample (a sample is typically blood, urine or cerebrospinal fluid (CSF)), to aid in the diagnosis or detection of disease. The information found from a test can be used to:
- Diagnose disease
- Assess the extent of damage
- Monitor the effectiveness of treatment
- Confirm a person to be free from disease
Blood flows through all parts of the body, coming into direct contact with every organ and tissue. Therefore a blood sample’s appearance and composition provide important information on what is happening in the various parts of the body!
Examples of substances that may be tested for the blood include proteins, nutrients, waste products, antibodies, hormones, salts, trace elements or vitamins.Ā These are sometimes referred to as āanalytesā, āmarkersā or ābiomarkersā.
This is where reagents come inā¦
A reagent is a substance which is mixed with the patient sample to create a chemical reaction to detect the biomarker.Ā These reactions are analysed by machines known as analysers.
Finallyā¦
Using data gathered from both clinical symptoms and laboratory tests, the doctor will follow a sometimes painstaking process of analysis and elimination to perform a successful diagnosis!
Randox Reagents celebrate World Kidney Day 2017
On 9 March 2017, Randox Reagents are celebrating World Kidney Day! World Kidney Day is a global campaign aimed at raising awareness of the importance of our kidneys to our overall health. It aims to reduce the frequency and impact of kidney disease and its associated health problems worldwide.
This year, the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviours an affordable option.
With this in mind, throughout the week we have been sharing on social media some interesting facts on diagnostic tests which can help aid an early risk assessment of kidney disease in obese patients, allowing preventative action to be taken before any serious damage occurs. The tests of focus this week included cystatin C, adiponectin and microalbumin…
Cystatin C
The creatinine test is routinely run for patients who are suspected for deteriorating kidney function, however this test has limitations. Cystatin C is an alternative test, and is particularly useful in patients where creatinine measurements are not suitable e.g. individuals who are obese, malnourished, have liver cirrhosis or reduced muscle mass. Importantly, unlike creatinine, cystatin C does not have a ‘blind area’ – up to 50% of kidney function can be lost before significant creatinine elevation occurs. Cystatin C is extremely sensitive to very small changes in kidney function and is therefore capable of detecting early stage kidney dysfunction. The cystatin C test therefore allows preventative measures to be taken much earlier and before significant kidney function decline.
Adiponectin
There is substantial evidence that excess visceral fat is the main driving force for almost all of the disorders associated with the metabolic syndrome, including CKD.1,2 The adiponectin test from Randox can accurately assess levels of abdominal visceral fat, independent of age, race or fitness level.3,4 Assessing adiponectin, and therefore visceral fat levels, can help assess risk of CKD, as well as a range of other illnesses such as pre-diabetes, CVD and various cancers.
Microalbumin
The microalbumin test detects very low levels of a blood protein called albumin, in urine. The detection of albumin in urine can be an indicator of kidney injury and can result in irreversible damage if left untreated. Low albumin concentrations in the urine are the earliest marker of kidney damage and therefore enable preventative measures to be taken. Microalbumin testing can identify individuals with diabetic nephropathy approximately 5-10 years earlier than proteinuria tests helping reduce the frequency of end stage renal disease.
Both World Kidney Day and Randox are working towards improving healthcare worldwide. With continuous investment in R&D, Randox are helping with the risk assessment and earliest detection of renal function problems. By assessing one’s risk of kidney problems (with the adiponectin test), it can give patients (obese and other) the tools to prevent kidney problems further on down the line. With early diagnosis (through the cystatin C and microalbumin tests) it will be possible to keep kidney problems from getting worse, therefore lowering the number of those diagnosed with CKD worldwide.
For health professionals
If you are a clinician or lab interested in running renal function assays, Randox offers a large range of high quality routine and niche assays including: Cystatin C, Creatinine Enzymatic and Jaffe, Microalbumin, Urinary Protein, Urea, Sodium, Potassium, Albumin, Ammonia, β2- Microglobulin, Calcium, Chloride, Glucose, HbA1c, IgG, LDH, Magnesium, Phosphorus (Inorganic), and Uric Acid. These can be run on most automated biochemistry analysers.
For more information, download our Diabetes Brochure or email reagents@randox.com.
References
- Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic renal disease?Adv Ren Replace Ther. 2004;11(1):41–54. [PubMed]
- Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update.Physiol Rev. 2013;93(1):359–404. [PubMed]
- Matsuzawa, Y. The role of fat topology in the risk of disease. Int J Obes. 2008;32:s83-s92.
- Frederiksen, L., Nielsen, T. L., Wraae, K., Hagen, C., Frystyk, J., Flyvbjerg, A., Brixen, K. and Andersen, M. Subcutaneous Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men. JCEM, (2009) 94 (10): 4010-4015.
Further reading:
What is Measurement of Uncertainty?
Measurement Uncertainty (MU) relates to the margin of doubt that exists for the result of any measurement, as well as how significant the doubt is. For example, a piece of string may measure 20 cm plus or minus 1 cm, at the 95% confidence level. As a result, this could be written: 20 cm ±1 cm, with a confidence of 95%. Therefore, we are 95% sure that the piece of string is between 19 cm and 21 cm long.
Standards such as ISO 15189 require that the laboratory must determine uncertainty for each test. However, they have not specified how this should be done.
How do we calculate Measurement Uncertainty using QC data?
Employing your QC data to calculate uncertainty makes several assumptions; your test system is under control, the patient samples are treated in the same manner as your controls and gross outliers have been removed. If you choose to use your QC data to calculate this you should ensure that you use a commutable control with a matrix similar to that of a patient sample, with analytes present at clinically relevant levels
To calculate MU, labs must look at the intra-assay precision and inter-assay precision of their test.
Intra-assay precision: Sometimes known as ‘within run’ precision, is where 20 or more replicates of the same sample are run at the same time, under the same conditions (calculated from a single experiment). Intra-assay precision helps to assess systematic uncertainties
Inter-assay precision: Sometimes known as ‘between run’ precision, is where 20 or more replicates are run at different times – e.g. 1 replicate every day for 20 days (can be calculated from routine IQC data). Inter-assay precision can help identify random uncertainties within the test system.
*The Australian Association of Clinical Biochemists (AACB) recommends that at least 6 months’ worth of QC data are used when calculating the inter-assay precision1.
Once the data is collected, you must calculate the standard error of the mean (SEM) of the intra-assay precision (A) and the SD of the inter-assay precision (B) in order to measure the uncertainty (u). Once A and B have been calculated, they need to be squared, added together and the square root of the sum found:
As uncertainty is calculated as SD and 1SD is equal to 68% confidence on a standard Gaussian curve, we can conclude that if we multiply using a coverage factor of 2, we can attain 2SD confidence of 95%. This is known as the Expanded Uncertainty (U):
What is the Advantage of Measurement Uncertainty for a lab?
Labs need to carry out MU as it is a requirement of ISO 15189. It states: “The laboratory shall determine measurement uncertainty for each measurement procedure, in the examination phases used to report measured quantity values on patients’ samples. The laboratory shall define the performance requirements for the measurement uncertainty of each measurement procedure and regularly review estimates of measurement uncertainty”.
MU also helps determine whether the difference between two results is negligible due to uncertainty or significant due to a genuine change in condition of the patient; giving labs a greater confidence in reported results.
How can Randox help?
Our new Acusera 24.7 Live Online software provides automatic calculation of MU, saving valuable time and helping labs meet ISO 15189 requirements with ease.
Contact marketing@randox.com to find out how your lab can benefit from Acusera 24.7 Live Online
Take steps to prevent incorrect patient results by making one simple change
According to the NHS Litigation Authority; in 2015 within the UK alone, £193,680,744.30 was spent on ‘wrong diagnosis’ or ‘failed/delayed diagnosis’ causing huge financial strain and impact on labs.
With approximately 75% of clinical decisions and diagnosis based on laboratory test results. The only way to guarantee a high degree of accuracy is to implement a good Quality Control plan. The importance of this is recognised globally, several bodies exist internationally including ISO (International organisation for standardisation) who have developed a set of guidelines and quality systems to ensure the reliability of laboratory test results.
So what can you do to improve accuracy and reliability?
Choose a third party QC
ISO 151589:2012 Section 5.6.2.2 states that “the use of third party control materials should be considered, either instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer”.
First Party Controls are those manufactured by the instrument/reagent manufacturer. These controls are optimised specifically for use with the manufacturers test system and therefore will mask a multitude of weaknesses. First Party Controls tend to result in perceived accuracy and a biased assessment of performance.
Third Party Controls on the other hand are designed to be completely independent and are not optimised for use with a specific test or system. Leading manufacturers of third party controls will assign target values based on data collected from thousands of independent laboratories, ensuring the availability of statistically robust multi-method, multi-analyser data. Therefore laboratories using Third Party Controls can be assured of unbiased error detection across multiple platforms.
Randox Acusera is a world leading manufacturer of true third party controls providing a cost effective, high quality solution for any laboratory-regardless of size or budget.
Look out for QC samples with clinically relevant concentrations
ISO 15189:2012 states that ‘The laboratory should choose concentrations of control materials wherever possible, especially at or near clinical decision values, which ensure the validity of decisions made’.
It is important to assess the full clinical range of an assay i.e. the range between the lowest and highest results which can be reliably reported. In order to make sure a laboratory instrument is performing accurately across the full clinical range and in particular at the medical decision level, QC materials that cover low, normal and elevated concentrations should be used.
Due to the superior manufacturing process used by Randox, QC target values consistently cover the MDL of tests. By ensuring the controls in use cover clinical decision levels laboratories can be confident of the reliability and accuracy of the patient results they release.
Opt for a commutable control material
A good QC material has many essential properties but above all, controls must perform consistently and reflect the performance of patient samples – if a control meets these requirements then we can say it is commutable. Having a commutable control would aid in the prevention of incorrect patient results because they replicate the performance of a patient sample and react to the test system in a similar manner. Use of a commutable control will also reduce costly shifts in QC target values when reagent batch is changed.
At Randox we take quality seriously, that’s why all QC products are manufactured to the highest possible standard, delivering controls of unrivalled quality. Designed to be commutable, the Acusera range will ensure accurate and reliable instrument performance while simultaneously helping laboratories to meet ISO 15189:2012 requirements. A good QC process will include the use of Third Party Controls, Clinically Relevant Concentrations and controls which can be described as commutable. By employing Quality Control’s that encompass these traits, a laboratory professional can be certain that they have taken the necessary steps to decrease incorrect results and therefore potential misdiagnosis.
